Medical Oncology, Год журнала: 2025, Номер 42(6)
Опубликована: Май 5, 2025
Язык: Английский
Medical Oncology, Год журнала: 2025, Номер 42(6)
Опубликована: Май 5, 2025
Язык: Английский
Ageing Research Reviews, Год журнала: 2025, Номер 104, С. 102657 - 102657
Опубликована: Янв. 7, 2025
Язык: Английский
Процитировано
5Cells, Год журнала: 2024, Номер 13(23), С. 1987 - 1987
Опубликована: Дек. 1, 2024
The gut microbiota significantly impacts human health, influencing metabolism, immunological responses, and disease prevention. Dysbiosis, or microbial imbalance, is linked to various diseases, including cancer. It crucial preserve a healthy microbiome since pathogenic bacteria, such as
Язык: Английский
Процитировано
14Advanced Functional Materials, Год журнала: 2024, Номер 34(40)
Опубликована: Апрель 25, 2024
Abstract The oral delivery of most atypical antipsychotics is severely challenged by their low bioavailability and significant food effects that necessitate patient compliance. Lipid formulations are an attractive system for overcoming the dosing challenges antipsychotics, but negative impact on gut microbiota can interfere with pharmacodynamic response through disruption gut‐brain axis. Here, novel microbiota‐targeting microcapsules engineered to provide a multifunctional approach improving both pharmacokinetic properties antipsychotic, lurasidone. comprised lipid core facilitates solubilization absorption lipophilic drug outer carbohydrate polymer (inulin) shell positively modulates facilitating microbial fermentation. Fed‐fasted variability in lurasidone mitigated microencapsulation inulin‐lipid (ILM), while enrichment coupled enhanced serotonin levels small intestine, faeces, plasma. realization ILM confirms pharmacokinetics efficacy mental health therapies, such as be optimized strategic encapsulation within functional target effective modulation
Язык: Английский
Процитировано
10Expert Opinion on Drug Delivery, Год журнала: 2023, Номер 20(10), С. 1315 - 1331
Опубликована: Июль 5, 2023
Introduction The trillions of microorganisms that comprise the gut microbiome form dynamic bidirectional interactions with orally administered drugs and host health. These relationships can alter all aspects drug pharmacokinetics pharmacodynamics (PK/PD); thus, there is a desire to control these maximize therapeutic efficacy. Attempts modulate drug-gut have spurred advancements within field 'pharmacomicrobiomics' are poised become next frontier oral delivery.Areas covered This review details exist between microbiome, clinically relevant case examples outlining clear motive for controlling pharmacomicrobiomic interactions. Specific focus attributed novel advanced strategies demonstrated success in mediating interactions.Expert opinion Co-administration gut-active supplements (e.g. pro- pre-biotics), innovative delivery vehicles, strategic polypharmacy serve as most promising viable approaches Targeting through presents new opportunities improving efficacy by precisely PK/PD, while mitigating metabolic disturbances caused drug-induced dysbiosis. However, successfully translating preclinical potential into clinical outcomes relies on overcoming key challenges related interindividual variability composition study design parameters.
Язык: Английский
Процитировано
22Journal of Hazardous Materials, Год журнала: 2024, Номер 472, С. 134444 - 134444
Опубликована: Апрель 30, 2024
Язык: Английский
Процитировано
7European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177509 - 177509
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
1Journal of Food Science, Год журнала: 2025, Номер 90(3)
Опубликована: Март 1, 2025
Abstract Intermittent fasting (IF) is an eating pattern that promotes health and cognitive improvement through periodic eating. It has been shown to enhance neuroplasticity reduce oxidative stress inflammation. Recent studies have demonstrated probiotic supplementation enhances performance by modulating gut microbiota composition increasing short‐chain fatty acid production, which in turn neurogenesis synaptic plasticity. The microbiota‐gut‐brain axis (MGBA) the communication bridge between brain, influencing function immune, endocrine, nervous systems. combination of probiotics IF may exert complementary effects on function, with enhancing microbial diversity metabolic efficiency, while further modulate barrier integrity neurotransmitter synthesis. This review critically examines interplay via MGBA, identifying key mechanisms potential therapeutic strategies remain underexplored current research.
Язык: Английский
Процитировано
1Metabolites, Год журнала: 2024, Номер 14(12), С. 683 - 683
Опубликована: Дек. 5, 2024
Background: The human digestive system contains approximately 100 trillion bacteria. gut microbiota is an emerging field of research that associated with specific biological processes in many diseases, including cardiovascular disease, obesity, diabetes, brain rheumatoid arthritis, and cancer. Emerging evidence indicates the affects response to anticancer therapies by modulating host immune system. Recent studies have explained a high correlation between breast cancer: dysbiosis cancer may regulate systemic inflammatory response, hormone metabolism, tumor microenvironment. Some bacteria are related estrogen which increase or decrease risk changing number hormones. Further, has been seen modulate respect its ability protect against treat cancers, focus on receptor-positive Probiotics other claiming control microbiome bacterial means might be useful prevention, even treatment, Conclusions: present review underlines various aspects clinical application, warranting individualized microbiome-modulated therapeutic approaches treatment.
Язык: Английский
Процитировано
6Biomedicines, Год журнала: 2024, Номер 12(12), С. 2776 - 2776
Опубликована: Дек. 6, 2024
The gut microbiota plays a crucial role in modulating anticancer immunity, significantly impacting the effectiveness of various cancer therapies, including immunotherapy, chemotherapy, and radiotherapy. Its impact on development is complex; certain bacteria, like
Язык: Английский
Процитировано
5Frontiers in Pharmacology, Год журнала: 2023, Номер 14
Опубликована: Янв. 25, 2023
Second-generation antipsychotics (SGAs) are the mainstay of treatment for schizophrenia and other neuropsychiatric diseases but cause a high risk disruption to lipid metabolism, which is an intractable therapeutic challenge worldwide. Although exact mechanisms underlying this disturbance complex, increasing body evidence has suggested involvement gut microbiota in SGA-induced dysregulation since SGA may alter abundance composition intestinal microflora. The subsequent effects involve generation different categories signaling molecules by microbes such as endogenous cannabinoids, cholesterol, short-chain fatty acids (SCFAs), bile (BAs), hormones that regulate metabolism. On one hand, these can directly activate vagus nerve or be transported into brain influence appetite via gut–brain axis. also related metabolism peripheral pathways. Interestingly, strategies targeting metabolites seem have promising efficacy disturbances. Thus, review provides comprehensive understanding how SGAs induce disturbances altering microbiota.
Язык: Английский
Процитировано
10